Moreover, in LGG, higher BCAT1 expression (TCGA, IDH1WT:35.7%; CGGA, IDH1WT:41.8%) is also connected with a worse overall survival time than lower BCAT1 expression (TCGA, IDH1WT:1.7%; CGGA, IDH1WT:7.1%) (Figure 2B, 2E), while in GBM, there is no significant difference between BCAT1 higher (TCGA, IDH1WT:100%; CGGA, IDH1WT:91.2%) and lower groups (TCGA, IDH1WT:86.5%; CGGA, IDH1WT:68.4%) (Figure 2C, 2F). This evidence concerns the gene BCAT1 and glioblastoma.